Diuretics
DrugDaily adjustments of diuretics and associated supplements based on cardiac filling pressures.
NCT Number: NCT01370564
This chronic, prospective, non-randomized feasibility study is designed to evaluate the Integrated Patient Care (IPC) concept in subjects who already have either a Medtronic Chronicle Implantable Hemodynamic Monitor (IHM) or Chronicle Implantable Cardioverter Defibrillator (ICD) device implanted, and are currently enrolled in the Chronicle Offers Management to Patients with Advanced Signs & Symptoms of Heart Failure (COMPASS-HF) Extension Phase Study (IDE # G020304). The purpose of the study is to use daily cardiac filling pressures from the Chronicle device to provide timely medication adjustments (diuretics) to subjects.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Ohio State University, Columbus, Ohio, United States
Subjects will be asked to transmit to the CareLink Network daily. Data specific to this study (subject's daily estimated Pulmonary Arterial Diastolic (ePAD) pressure values) will be extracted from the CareLink database and transferred to the IPC clinician website.
As each subject is enrolled, clinicians at each participating site will determine the appropriate target pressure range for each subject based on a review of the subject's pressure data. Each day after enrollment, the subject's current pressure data will be compared to a target pressure range that the clinician sets for that subject.
The patient instruction set (PtIS) is limited to a daily diuretic prescription and associated supplements, per physician discretion. The PtIS should not include adjustments of non-heart failure medications and should not include heart failure medications that are not indicated for day-to-day adjustments (e.g. ACE-Inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-Blockers). The PtIS will be sent from the IPC clinician website to the subject through a Patient Home Monitor.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Time frame: Baseline through Completion/Exit (an average of 3 months)
The proportion of study days a PtIS is based on the subjects' daily pressure state
Time frame: Baseline through Completion/Exit (an average of 3-months)
The frequency of changes in the IPC setup during the study (an average of 3-months).
Time frame: Baseline through Completion/Exit (on average 3-months)
The proporition of IPC days study subjects indicated they complied with their PtIS.
Time frame: Baseline through Completion/Exit (an average of 3-months)
Changes in brain natriuretic peptide from baseline to study exit (an average of 3-months).
Time frame: Baseline through Completion/Exit (an average of 3-months)
All serious adverse events, cardiovascular adverse events, and event related to the IPC system will be documented and summarized.
Time frame: Baseline through Completion/Exit (an average of 3-months)
Changes in estimated glomular filtration rate from baseline to study exit (an average of 3-months).
Time frame: Baseline through Completion/Exit (an average of 3-months)
Changes in blood urea nitrogen from baseline to study exit (an average of 3-months).
Medtronic Cardiac Rhythm and Heart Failure
Industry
Acronym: IPC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07743125
Cardiovascular Diseases, Heart Diseases
Menomonee Falls, Wisconsin, United States
View Trial DetailsNCT03446651
Cardiovascular Diseases, Heart Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT05806606
Behavior, Cardiovascular Diseases
Hong Kong
View Trial DetailsNCT06847438
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial Details